coronary artery bypass
The Oxford Companion to the Body
|
2001
|
|
© The Oxford Companion to the Body 2001, originally published by Oxford University Press 2001. (Hide copyright information)
Copyright
coronary artery bypass is a surgical procedure for treating patients with obstructions in their
coronary arteries. The procedure overcomes the effects of the obstructions, while not directly influencing their underlying causes. The operation was first used in substantial numbers in the late 1960s; it has now become one of the most commonly undertaken surgical operations.
The muscular pumping chambers of the
heart require a copious blood supply, which is conducted by the left and right coronary arteries and their branches. These lie on or near the surface of the heart, giving rise to small vessels which penetrate into the muscle to supply the nutrient capillary networks surrounding individual heart muscle cells.
In many populations, particularly where cigarette
smoking, diets rich in saturated
fats, low
exercise activity,
diabetes, and high
blood pressure are prevalent, the coronary arteries are frequently affected by the process known as
atherosclerosis. This is a degenerative disease of arteries characterized by development of fatty accumulations within the inner portion of the arterial wall, separated from the blood by a fibrous layer or plaque. These lesions predominantly affect the coronary arteries on the surface of the heart, near their origins from the aorta, sparing arteries further downstream (thus fortuitously making bypass surgery feasible).
Atherosclerotic lesions may gradually expand, narrowing the coronary artery, over many years, ultimately restricting blood flow to the heart muscle. This prevents an increase in blood supply to the heart muscle when it is most needed (e.g. during exercise or emotion), and results in an unpleasant, constricting, central chest pain known as
angina.
Another possibility is rupture of the fibrous plaque with release of the fatty material and clotting of the blood within the coronary artery, abruptly interrupting the blood supply to a portion of the
heart muscle. This is manifested clinically as a heart attack, which may be fatal, may leave part of the heart muscle permanently scarred, or may be followed by near-complete recovery, particularly if the clot breaks up rapidly (spontaneously or in response to
thrombolytic drugs).
The coronary arteries, and any obstructions, can be demonstrated by the procedure of
coronary angiography. The passage of a radio-opaque fluid is recorded by cine-radiography, following its injection into the coronary arteries via long catheters introduced through a conveniently placed peripheral artery (e.g. the femoral artery in the groin).
Coronary artery bypass is usually used for treating angina, particularly in those found to have obstructions in multiple coronary arteries, or obstructions at strategic sites. Bypass surgery may be appropriate even when angina is not present, if coronary angiographic study after a ‘coronary event’ (usually a heart attack) shows severe coronary disease. Coronary artery bypass is only one of the possible treatment options, which include drug therapy and cardiological interventions such as
angioplasty (inflation of a small balloon at the site of obstruction) and
stenting (placing a tubular mesh at the expanded site to help keep it open). Surgery is usually reserved for patients with more extensively diseased coronary arteries where angioplasty may be less successful or impractical.
In principle, the operation consists of placing a conduit to conduct blood to the coronary artery beyond the obstruction. The heart is exposed by dividing the sternal bone vertically, and a heart–lung machine is used to maintain the general body circulation while the heart is immobilized to allow work on the coronary arteries. The superficial veins of the legs provide a good source of bypass conduit. The
internal mammary artery, which lies to the side of the sternum, can be used as a particularly useful conduit for bypassing the anterior descending coronary artery branch. Other arteries, such as the radial artery from the forearm, may also be used as conduits. The coronary artery is opened for a few millimetres at a suitable site beyond the obstruction and the end of the conduit is sewn to the opened artery. The other end of the conduit is sewn to an opening made in the aorta a few centimetres downstream from the natural openings of the coronary arteries, except in the case of the internal mammary artery, when its origin is left undisturbed. Usually several conduits are required, commonly three or four arteries being bypassed. The coronary arteries are typically 1–3 mm in diameter, and magnification is used to enhance surgical precision. If there is extensive coronary obstruction it may be difficult to find a suitable site for insertion of a bypass conduit. In this case it is often possible to open into the diseased artery and extract the atheromatous occlusion from a sufficiently long segment to allow a bypass graft to be inserted (the procedure known as
endarterectomy).
There is a mortality rate for this operation, usually about 1–3%, and
stroke, bleeding, impaired cardiac function, and chest infections are among the early complications which may occur, depending on age and physical condition.
Bypass of all severe obstructions restores normal blood supply to the heart muscle on exercise. Angina is abolished and normal life can usually be resumed. Over subsequent years there is a gradual return of angina, such that up to 50% of patients have some recurrent symptoms by 10 years after surgery, some even requiring further surgery. Recurrent angina is due either to progression of disease in the coronary arteries to affect new areas, or blocking of conduits (particularly vein conduits) by a process similar to atherosclerosis.
Coronary artery bypass can ameliorate the consequences of subsequent plaque rupture in a bypassed artery. This has been shown to improve the survival prospects of those patients who have multiple major coronary branch obstructions, particularly when there is damage to the heart muscle from previous heart attack.
In attempts to simplify the operation, efforts have been made to undertake coronary bypass without using the heart–lung machine, while the heart is beating, and
video-assisted minimal access techniques are being developed. These methods are presently feasible only in a small proportion of patients, usually with limited disease.
David Weatherall
Bibliography
Millner, R. and and Treasure, T. (1995). Explaining cardiac surgery: patient assessment and care. BMJ Publishing Group, London.
Cite this article
Pick a style below, and copy the text for your bibliography.
|
Optimal selection and delivery of a thrombolytic drug. (Current Status of Thrombolysis in Acute Myocardial Infarction, part 1)
Magazine article from: Chest; 1/1/1995; ; 700+ words
; ...AMI. [TABULAR DATA OMITTED] WHICH THROMBOLYTIC DRUG IS THE OPTIMAL THROMBOLYTIC DRUG? Overview of Three Commercially Available Thrombolytic Agents Three thrombolytic drugs, streptokinase (SK), tissue plasminogen activator (t-PA), and...
|
|
Conservative vs. Aggressive Treatment.(use of thrombolytic drugs for heart attacks)(Brief Article)(Statistical Data Included)
Magazine article from: USA Today (Magazine); 2/1/2001; 700+ words
; ...heart attack and treated with thrombolytic agents, or clot-busters...readministration of the thrombolytic agent, or an emergency revascularization...international, multicenter thrombolytic trials conducted six years...readministration of clot-busting drugs and how and when to utilize...after ...
|
|
Novel Thrombolytic Drug Cleared by FDA for Phase II Clinical Testing; TIMI Study Group to Conduct Phase II Trial of BB-10153 in Acute Myocardial Infarction.
Business Wire; 3/26/2002; 700+ words
; ...ahead to test the novel thrombolytic (`clot busting...10153 showed that the drug may overcome the risk...currently-prescribed thrombolytic drugs. This is because BB...1999 and showed the drug to be safe and well...agent. In preclinical thrombolytic studies, the selective...
|
|
Beijing Second Pharmaceutical markets third generation thrombolytic drug.
Newspaper article from: China Business News; 6/27/2006; 698 words
; ...regions. "The advantage of the drug lies in that it is administered...been marketing cardiovascular drugs for long time and has set up...predict the future sales of the drug. Since the third generation...the second generation of thrombolytic drugs still has their market. Beijing...
|
|
FDA CLEARS THROMBOLYTIC DRUG FOR PHASE II CLINICAL TRIAL.
Newspaper article from: Worldwide Biotech; 5/1/2002; 700+ words
; ...ahead to test the novel thrombolytic ("clot busting...10153 showed that the drug may overcome the risk...currently-prescribed thrombolytic drugs. This is because BB...as an inactive pro-drug, activated only at...agent. In preclinical thrombolytic studies, the ...
|
|
Better late than never: late use of clot busters may still save lives. (thrombolytic drugs for heart patients)
Magazine article from: Prevention; 6/1/1993; ; 684 words
; ...period, though--by then thrombolytic drugs are considered useless and...called the Late Assessment of Thrombolytic Efficacy (or LATE), patients...the group receiving the real drug, mortality was reduced by...a benefit in giving these drugs to patients who arrive 'late...
|
|
Stroke, Catheter Occlusion Trials Ongoing Nuvelo Still Seeking Efficacy of Thrombolytic Drug Alfimeprase.
Magazine article from: BIOWORLD Today; 1/28/2008; ; 700+ words
; ...planned to move forward with the thrombolytic agent in ischemic stroke and...has proven to be a difficult drug to get through the development...protein that inactivates the thrombolytic activity of alfimeprase, the drug tended to yield poorer efficacy...
|
|
Approach Shows Promise for Delivering Thrombolytic Drug.
Newspaper article from: Blood Weekly; 3/30/2000; 700+ words
; ...improve the delivery of enzyme drugs, according to researchers...their attempts in improving thrombolytic drug delivery in a study titled...directed, but inactive, enzyme drugs, and thereafter, a triggered...plasminogen activator as a model drug," Liang et al. wrote in...directed, but ...
|
|
Progen Scientists Profile Mechanism of PI-88 as Novel Antithrombotic at IBC's 11th Annual International Symposium - Advances in Anticoagulant, Antithrombotic and Thrombolytic Drugs.
Business Wire; 10/4/2000; 700+ words
; ...88 from many other anti-thrombotic drugs Listed as one of the symposium highlights...manufacturing facility that manufactures drug candidates under GMP for clinical trials...patients under an Investigational New Drug submission with the United States Food and Drug Administration and the Clinical ...
|
|
Study concludes premarketing drug trials underpowered.(tadalafil)(thrombolytic therapy)(COX-2 inhibitor )(salmeterol)(azithromycin)
Newspaper article from: Sports Medicine Reports; 7/1/2002; ; 700+ words
; ...drug reactions, and that many drugs have limited postmarketing...threshold for approving new drugs, especially when safe and...clinicians should be wary of new drugs and should immediately report adverse drug reactions to Medwatch, the...2003 launch is likely. New Thrombolytic ...
|
|
thrombolytic drug
Book article from: The Columbia Encyclopedia, Sixth Edition
thrombolytic drug or clot-dissolving drug, substance, such as streptokinase or tissue plasminogen activator (tPA), that causes the breakdown of blood clots (see thrombosis ) that obstruct the flow of blood through the vessels. Its uses...
|
|
Thrombolytic Therapy
Encyclopedia entry from: Gale Encyclopedia of Medicine, 3rd ed.
...therapy uses drugs called thrombolytic agents, such as alteplase...dissolve clots. These drugs are given as injections...physician supervising thrombolytic therapy decides on...account the type of drug, the purpose for which...weight. Precautions For thrombolytic therapy to be ...
|
|
Anticoagulant and Antiplatelet Drugs
Encyclopedia entry from: Gale Encyclopedia of Medicine, 3rd ed.
...Purpose Anticoagulant drugs reduce the ability of...strokes. Although these drugs are sometimes called...formed, although the drug stops an existing clot...However, another type of drug, used in thrombolytic therapy, will dissolve...clots. Anticoagulant drugs are used for a number...
|
|
clot-dissolving drug
Book article from: The Columbia Encyclopedia, Sixth Edition
clot-dissolving drug see thrombolytic drug .
|
|
Blood Clot Dissolving Agent
Book article from: Medical Discoveries
...Three groups of thrombolytic agents are available...plasminogen. All these drugs digest clots by increasing...bacteria to produce this drug. Although streptokinase...combined with other drugs, because it is difficult...affordable. Each of these thrombolytic agents shows great...
|